Skip to main content
Premium Trial:

Request an Annual Quote

JCSG Scripps Collaborates with Rigaku

NEW YORK (GenomeWeb News) – The Joint Center for Structural Genomics has acquired a crystal imaging system from Rigaku Americas, and is using it in a collaboration with the Desktop Minstrel UV system it acquired in 2008, Rigaku said today.

Rigaku said it is working with JCSG on an automated ultraviolet imaging and protein crystal monitoring system that will supplement the existing large-scale, high-throughput Rigaku CrystalMation system at the JCSG robotic crystallization facility at the Scripps Research Institute.

JCSG is a multi-institutional consortium at Scripps, and at the University of California, San Diego, the Burnham Institute for Medical Research, and Stanford University.

JCSG Core Manager Marc Elsliger said in a statement that the institute aims to use the new UV imaging technology to decipher protein from salt crystals, technology which could "be harnessed for automated identification of protein crystals and, more importantly, a more reliable and quantitative autoscoring of the crystallization trials."

Financial terms of the agreement were not released.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.